CD47 and CD68 expression in breast cancer is associated with tumor‐infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis

CD47 expressed on tumor cells binds to signal regulatory protein alpha on macrophages, initiating inhibition of phagocytosis. We investigated the relationships between tumor expression of CD47 and CD68 macrophage content, subsets of tumor‐infiltrating lymphocytes (TILs), and vascular invasion in breast cancer. A population‐based series of 282 cases (200 screen detected and 82 interval patients) from the Norwegian Breast Cancer Screening Program was examined. Immunohistochemical staining for CD47 and CD68 was evaluated on tissue microarray (TMA) slides. For CD47 evaluation, a staining index was used. CD68 tumor‐associated macrophages were counted and dichotomized. TIL subsets (CD45, CD3, CD4, CD8, and FOXP3) were counted and dichotomized using immunohistochemistry on TMA slides. Vascular invasion (both lymphatic and blood vessel) was determined on whole tissue slides. High CD47 tumor cell expression or high counts of CD68 macrophages were significantly associated with elevated levels of all TIL subsets (p < 0.02), CD163 macrophages (p < 0.001), blood vessel invasion (CD31 positive) (p < 0.01), and high tumor cell Ki67 (p < 0.004). High CD47 expression was associated with ER negativity (p < 0.001), HER2 positive status (p = 0.03), and interval‐detected tumors (p = 0.03). Combined high expression of CD47–CD68 was associated with a shorter recurrence‐free survival (RFS) by multivariate analysis (hazard ratio [HR]: 2.37, p = 0.018), adjusting for tumor diameter, histologic grade, lymph node status, and molecular subtype. Patients with luminal A tumors showed a shorter RFS for CD47–CD68 high cases by multivariate assessment (HR: 5.73, p = 0.004). This study demonstrates an association of concurrent high CD47 tumor cell expression and high CD68 macrophage counts with various TIL subsets, blood vessel invasion (CD31 positive), other aggressive tumor features, and interval‐presenting breast cancer. Our findings suggest a link between CD47, tumor immune response, and blood vessel invasion (CD31 positive). Combined high expression of CD47–CD68 was an independent prognostic factor associated with poor prognosis in all cases, as well as in the luminal A category.

[1]  L. Akslen,et al.  Tumor‐associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer , 2021, The journal of pathology. Clinical research.

[2]  Caroline Yu,et al.  CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor , 2021, BMC cancer.

[3]  L. Conti,et al.  The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy , 2021, Frontiers in Oncology.

[4]  T. Tsuzuki,et al.  Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer , 2021, International journal of molecular sciences.

[5]  I. Hedenfalk,et al.  Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression , 2021, Breast cancer research : BCR.

[6]  K. Lam,et al.  Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells , 2020, Nature Communications.

[7]  Jin-jian Lu,et al.  Regulation of CD47 expression in cancer cells , 2020, Translational oncology.

[8]  R. Petrie,et al.  Regulation of extracellular matrix assembly and structure by hybrid M1/M2 macrophages , 2020, bioRxiv.

[9]  Jianguo Xu,et al.  CD47: the next checkpoint target for cancer immunotherapy. , 2020, Critical reviews in oncology/hematology.

[10]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[11]  C. Evans,et al.  Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis , 2020, Frontiers in Immunology.

[12]  K. Yin,et al.  Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer , 2019, Journal of Immunotherapy for Cancer.

[13]  M. Pan,et al.  Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer , 2019, Journal of Hematology & Oncology.

[14]  L. Jia,et al.  Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy , 2019, OncoTargets and therapy.

[15]  Chuang Chen,et al.  Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients , 2019, Cancer Cell International.

[16]  Liang Li,et al.  CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer. , 2019, American journal of translational research.

[17]  Chuang Chen,et al.  High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis , 2019, Oncology letters.

[18]  Y. Xi,et al.  Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia. , 2019, Pathology, research and practice.

[19]  T. Shien,et al.  Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer , 2018, Oncology letters.

[20]  C. Querfeld,et al.  Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience , 2018, Current opinion in oncology.

[21]  T. Matozaki,et al.  CD47‐signal regulatory protein α signaling system and its application to cancer immunotherapy , 2018, Cancer science.

[22]  A. Kulkarni,et al.  Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma , 2018, Oncoimmunology.

[23]  Junjeong Choi,et al.  The role of tumor-associated macrophage in breast cancer biology. , 2018, Histology and histopathology.

[24]  C. Zahnow,et al.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells , 2018, Proceedings of the National Academy of Sciences.

[25]  Michelle R. Dawson,et al.  Microenvironment Influences Cancer Cell Mechanics from Tumor Growth to Metastasis. , 2018, Advances in experimental medicine and biology.

[26]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[27]  Bingshu E. Chen,et al.  Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial , 2017, JAMA oncology.

[28]  L. Akslen,et al.  Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer. , 2017, Human pathology.

[29]  G. Aydoğ,et al.  Relationship between immunohistochemical staining extent of CD47 and histopathologic features of bladder tumor , 2017, Central European journal of urology.

[30]  O. Arrieta,et al.  CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients , 2017, British Journal of Cancer.

[31]  Z. Yao,et al.  CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis , 2017, Oncotarget.

[32]  H. Matlung,et al.  The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer , 2017, Immunological reviews.

[33]  Ting Wu,et al.  Tumor microenvironment and therapeutic response. , 2017, Cancer letters.

[34]  Z. Yao,et al.  Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. , 2017, Journal of thoracic disease.

[35]  Zihai Li,et al.  Is CD47 an innate immune checkpoint for tumor evasion? , 2017, Journal of Hematology & Oncology.

[36]  Lu Gao,et al.  CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis , 2016, Oncotarget.

[37]  T. Aas,et al.  Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival , 2016, Journal of Clinical Pathology.

[38]  Zhijie Kang,et al.  CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer , 2016, Scientific Reports.

[39]  Daoud M. Meerzaman,et al.  A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer , 2016, Oncotarget.

[40]  Wen-Wei Hu,et al.  Tumor-associated macrophages in cancers , 2016, Clinical and Translational Oncology.

[41]  R. Vonderheide,et al.  CD47 blockade as another immune checkpoint therapy for cancer , 2015, Nature Medicine.

[42]  I. Weissman,et al.  Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 “Don't Eat Me” Signals , 2015, Clinical Cancer Research.

[43]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  D. Soto-Pantoja,et al.  CD47 Signaling Regulates the Immunosuppressive Activity of VEGF in T Cells , 2014, The Journal of Immunology.

[45]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  T. Holland-Letz,et al.  Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients , 2014, Oncotarget.

[47]  P. Lu,et al.  Blockade of CD47‐mediated cathepsin S/protease‐activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma , 2014, Hepatology.

[48]  Eduard Batlle,et al.  Metastatic stem cells: sources, niches, and vital pathways. , 2014, Cell stem cell.

[49]  P. Eggleton,et al.  A CD47‐blocking TRAIL fusion protein with dual pro‐phagocytic and pro‐apoptotic anticancer activity , 2014, British journal of haematology.

[50]  A. Goldhirsch.  Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient. , 2013, Breast.

[51]  O. Olopade,et al.  The role of tumor-associated macrophages in breast cancer , 2015 .

[52]  L. Martiny,et al.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.

[53]  G. Newton,et al.  Endothelial CD47 Promotes Vascular Endothelial-Cadherin Tyrosine Phosphorylation and Participates in T Cell Recruitment at Sites of Inflammation In Vivo , 2012, The Journal of Immunology.

[54]  A. Orimo,et al.  Emerging roles of the tumor-associated stroma in promoting tumor metastasis , 2012, Cell adhesion & migration.

[55]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[56]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[57]  Andrew H. Beck,et al.  Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma , 2012, Proceedings of the National Academy of Sciences.

[58]  D. Roberts,et al.  CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2 , 2011, Cell cycle.

[59]  D. Tran,et al.  T regulatory cells in cancer: recent advances and therapeutic potential , 2010, Expert opinion on biological therapy.

[60]  K. Mimori,et al.  Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients , 2010, Clinical Cancer Research.

[61]  I. Weissman,et al.  Macrophages as mediators of tumor immunosurveillance. , 2010, Trends in immunology.

[62]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[63]  Lajos Pusztai,et al.  Gene-expression signatures in breast cancer. , 2009, The New England journal of medicine.

[64]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[65]  E. Lo,et al.  Neurovascular effects of CD47 signaling: Promotion of cell death, inflammation, and suppression of angiogenesis in brain endothelial cells in vitro , 2009, Journal of neuroscience research.

[66]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[67]  A. Barclay,et al.  Signal regulatory protein alpha (SIRPalpha)/CD47 interaction and function. , 2009, Current opinion in immunology.

[68]  A. Sica,et al.  Plasticity of Macrophage Function during Tumor Progression: Regulation by Distinct Molecular Mechanisms1 , 2008, The Journal of Immunology.

[69]  D. Wink,et al.  CD47 Is Necessary for Inhibition of Nitric Oxide-stimulated Vascular Cell Responses by Thrombospondin-1* , 2006, Journal of Biological Chemistry.

[70]  A. Harris,et al.  Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer , 2000, The Journal of pathology.

[71]  L. Akslen,et al.  Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma , 1997, International journal of cancer.